Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs).
When parents and physicians Drs Zachary and Geri Landman learned that their newborn daughter Lucy had an ultra-rare genetic condition, they were devastated.
